⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Positron-Emission Tomography|Immunomodulation|Metastatic Solid Malignancies|Hodgkin Lymphoma
Interventions: DRUG: ⁸⁹Zr-Df-IAB22M2C Infusion
Sponsor: ImaginAb, Inc.